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Abstract: Alcoholic-dilated Cardiomyopathy (ACM) is the most prevalent form of ethanol-induced 
heart damage. Ethanol induces ACM in a dose-dependent manner, independently of nutrition, 
vitamin, or electrolyte disturbances. It has synergistic effects with other heart risk factors. ACM 
produces a progressive reduction in myocardial contractility and heart chamber dilatation, leading 
to heart failure episodes and arrhythmias. Pathologically, ethanol induces myocytolysis, apoptosis, 
and necrosis of myocytes, with repair mechanisms causing hypertrophy and interstitial fibrosis. 
Myocyte ethanol targets include changes in membrane composition, receptors, ion channels, 
intracellular [Ca2+] transients, and structural proteins, and disrupt sarcomere contractility. Cardiac 
remodeling tries to compensate for this damage, establishing a balance between aggression and 
defense mechanisms. The final process of ACM is the result of dosage and individual 
predisposition. The ACM prognosis depends on the degree of persistent ethanol intake. Abstinence 
is the preferred goal, although controlled drinking may still improve cardiac function. New 
strategies are addressed to decrease myocyte hypertrophy and interstitial fibrosis and try to 
improve myocyte regeneration, minimizing ethanol-related cardiac damage. Growth factors and 
cardiomyokines are relevant molecules that may modify this process. Cardiac transplantation is the 
final measure in end-stage ACM but is limited to those subjects able to achieve abstinence. 
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1. Introduction 
Ethyl alcohol, also known as “ethanol” or usually just as “alcohol”, is the most consumed drug 
in human history [1]. At present, its consumption rates are still very high, with a widespread 
worldwide distribution, in a global uncontrolled scenario with easy access [2]. In fact, there is an 
increasing consumption in particular groups, such as adolescents and young people [3,4].  
This ethanol misuse at high consumption rates causes a variety of health problems, ethanol 
being the sixth most relevant factor of global burden of disease and responsible for 5.3% of all deaths 
[5]. Despite this clear epidemiological evidence of ethanol’s unsafe consumption and increased 
health risk, results of consumption policies are not effective enough. Therefore, the need to establish 
a more effective control on ethanol consumption has been repeatedly claimed [2].  
It has been said that ethanol is the “perfect drug” because of its pleasant effects but damaging 
long-term effect [1,6]. It is distributed worldwide, with easy social access, and is pleasant when 
consumed, with positive sensations of welfare, but its negative effects, which include depressive and 
damaging noxious health effects, are reserved for later. This dual effect creates an additional 
difficulty to achieve an effective control. Ethanol is one of the most addictive drugs for humans, with 
high physical and psychological addiction potential [7]. Efforts to control alcohol addiction have just 
50%–60% positive results in specific cessation programs [8,9]. 
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One of the characteristics that makes ethanol harmful is its systemic toxic effect on the human 
body [10,11]. It has been described as having some kind of effect in all human body organs either in 
acute or chronic consumption [11,12]. The liver is the most affected organ, since ethanol is mostly 
metabolized there [11,13], but gastrointestinal, central, and peripheral nervous systems; the heart 
and vascular system; endocrinological systems; nutrition; and musculo-skeletal systems are clearly 
affected [10]. In addition, ethanol is an immunosuppressive drug that is pro-inflammatory and 
pro-oncogenic [14–17].  
In fact, the particular effects that ethanol produces in a specific organ depend on several factors 
[18,19]. One is the physical characteristics of ethanol itself, with a low molecular size, high 
distribution capacity, and high tissue reactivity. Ethanol has active metabolites 
(acetaldehyde-acetate, fatty-acid ethyl esters), is a potent enzymatic inductor [20,21], and interacts 
with other drugs [22], but its effect also depends on the characteristics of the target organ, with 
excitable (brain, heart) [23] and metabolic (liver, pancreas) organs [24] being more susceptible to 
ethanol-induced organ damage. In addition, there is a relevant role on each organ, particularly on 
defense and adaptive mechanisms, with a clear induction of anti-oxidant, metabolic, and 
anti-inflammatory protective responses as a result of ethanol aggression [18,25,26]. This 
multi-factorial effect is attributed to genetic factors [27] and ethnic [28] variability. The final damage 
is an equilibrium between the intensity of damaging effects and the possibility of defense, plasticity, 
regeneration, and adaptation for every specific organ [29–31]. Thus, alcohol-dilated cardiomyopathy 
(ACM) is the result of dosage and individual predisposition [32]. 
The cardiovascular system is, after the liver and gastrointestinal system, the second most 
affected system by global ethanol toxicity [1,33,34]. At a high dose (more than 60 g/day for men and 
40 g/day for women) and chronic consumption (usually more than 10 years), ethanol increases the 
atherosclerosis process with coronary, cerebral, and peripheral vascular involvement [35,36], 
increases arterial hypertension [37], and causes progressive myocardial damage (alcoholic dilated 
cardiomyopathy—ACM) [18,38–41] as well as induction of arrhythmias [42,43]. The effect of a low 
dose of alcohol consumption on the cardiovascular system has been also extensively evaluated with 
evidence of a dual effect, beneficial for coronary artery disease at low doses [44] but reversing to a 
damaging effect at moderate to high doses [19]. Although there is beneficial potential in some 
patients, the coexistence of increased risk of cancer, neurological brain damage, and the high risk of 
ethanol addiction makes it necessary to discourage this low-dose consumption in the general 
population [19,41,45]. Specific caution should be recommended regarding children or adolescents [4] 
and women [46], who are more susceptible to the damaging effects of ethanol at the same doses of 
consumption as men. Similarly, patients suffering from other ethanol-related diseases such as liver 
cirrhosis or brain atrophy should completely suppress their ethanol consumption [47,48]. Therefore, 
the only safe ethanol dose for the cardiovascular system is zero [41,45,49–51].  
In this review, we specifically describe and discuss the global effects that ethanol exerts on the 
heart myocytes, the so-called alcoholic cardiomyopathy (ACM). 
2. What is Alcoholic Cardiomyopathy 
The first clinical recognition of ACM was performed by Hippocrates in Greece during the 4th 
century B.C. However, its modern clinical report was delayed until the 19th century, where specific 
ACM cases were clinically described in Germany and England [1]. During the 20th century, the 
physiopathological basis for ACM was progressively established [6]. At present, ACM is defined as 
a dilated cardiomyopathy of toxic origin with low left-ventricle ejection fraction, chamber dilatation, 
and progression to congestive heart failure [18,52,53]. Excessive EtOH consumption is one of the 
main causes of non-ischemic dilated cardiomyopathy (CMP), representing around one-third of cases 
[30]. 
2.1. The Natural Course of ACM 
At clinical level, the course of ACM is similar to idiopathic dilated CMP [54]. The subject with 
excessive alcohol consumption, after more than 10 years of high ethanol consumption, usually 
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develops subclinical heart functional changes before symptom appearance or signs of heart failure 
[55,56]. These may be detected with echosonography in around one-third of high-dose chronic 
consumers with preliminary evidence of subclinical left-ventricle (LV) diastolic dysfunction before 
progression to subclinical LV systolic dysfunction [57]. 
Symptoms of ACM are not specific and overlap with other forms of heart failure [30,41,58]. 
They appear when ventricle dilatation, hypertrophy, and dysfunction are established. Later and 
progressively in the course of the disease, around 20% of women and 25% of men with excessive 
alcohol consumption develop exertion dyspnea and orthopnea, leading to episodes of left-ventricle 
heart failure [39,46,59]. Depression of LV ejection fraction (EF) is the hallmark of this period that also 
occurs with a reduction in LV shortening fraction, increase in LV diameter, and mass indices that 
may be measured by echocardiography or cardiac MR spectroscopy [40,52]. Congestive symptoms, 
such as the expression of right ventricular failure, with peripheral edema or anasarca, are 
characteristic of advanced cases of ACM [42,56].  
A diverse variety of arrhythmias appear early and may worsen the course of ACM, atrial 
fibrillation being the most frequent [60] and ventricular tachycardia the most deleterious [61]. These 
arrhythmias are usually related to episodes of binge drinking [43,62] and are more frequent in 
established ACM than in subjects with normal cardiac function [52]. In chronic alcoholics, 
arrhythmia may frequently appear in relation to episodes of ethanol abstinence because of the 
increased release of catecholamines and electrolyte deficiencies [19]. 
Along with developing heart damage, patients with ACM may also damage other organs, such 
as the liver, central and peripheral nervous system, skeletal muscle, pancreas, and digestive tract, 
and are exposed to an increased risk of cancer [24,63,64]. In fact, ACM is related to systemic damage 
induced by ethanol misuse and its global biological response [10,11,31].  
Mortality in ACM is related to the progression of heart failure and malignant arrhythmias 
[58,65]. In long-term follow-up studies, a mortality rate of 10% of patients/year has been observed in 
the group of patients with persistent high-dose ethanol consumption [19,52]. 
2.2. Is ethanol the Real Cause of ACM 
Before recognizing that ethanol itself is the etiological factor of ACM, different theories and 
hypotheses emerged [1,66]. It was suspected that malnutrition, frequently related to chronic alcohol 
misuse, was the origin of ACM [6,67]. However, it has been evidenced that ACM may develop in the 
absence of protein or caloric malnutrition [38]. However, nutritional factors may worsen the natural 
course of ACM and should be avoided [18,19].  
Occidental Berberi is the term used for the clinical scenario caused by thiamine deficit, a 
situation commonly present in chronic alcohol misuse, and was attributed as the cause of ACM 
[68,69]. Similarly, electrolyte (Na, K, Ca, Mg, P) deficiencies or disturbances may play a major role in 
cardiac function, and ethanol misuse may be related to them [52]. Selenium deficit (Keshan disease 
in China) could also induce ACM in specific areas [70]. 
Another curious hypothesis from Germany suspected that some ethanol additives, such as 
anti-foam beer products with arsenic or cobalt content, produced cardiac toxicity and development 
of ACM [71]. However, there is no clear demonstration of this contaminant effect. Therefore, it is 
evident that ACM may develop with normal serum thiamine and electrolyte levels [38,66]. 
Consumption of other drugs such as cocaine or tobacco may interact with ethanol and potentiate the 
final ethanol-related cardiac damage [22,72]. 
2.3. Ethanol or Acetaldehyde 
One relevant question concerning ethanol cardiac toxicity is if ethanol itself or its active 
metabolite acetaldehyde causes cardiac damage [73,74]. In fact, both molecules are directly 
cardiotoxic, decreasing structural protein synthesis and heart contractility and increasing oxidative 
and metabolic damage, leading to autophagy [20,75]. In experimental studies, acetaldehyde directly 
impairs cardiac contractile function [76], disrupts cardiac excitation–contraction coupling, and 
promotes oxidative damage and lipid peroxidation [20]. Acetaldehyde is produced at a lower 
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quantity in the heart as compared to the liver, and systemic acetaldehyde does not achieve toxic 
heart concentrations [77]. In addition, acetaldehyde is able to interact with proteins and produce 
protein-adduct compounds that are highly reactive and may induce additional inflammatory and 
immunologic heart damage [78]. Therefore, because of its multiple actions, acetaldehyde may 
influence ACM pathogenesis in addition to ethanol effect itself [20,76,77].  
2.4. The dose-Related Effect of Ethanol and Beverage Types on the Heart 
Until the second part of the 20th century, there was no scientific evidence on the direct and 
dose-dependent effect of ethanol on the heart as cause of ACM [6,38]. This is a longstanding 
accumulated effect that usually appears when a subject has, in their lifetime, consumed more than 7 
Kg of ethanol per Kg of body weight in men (equivalent to 60 drinks per month), and 5 Kg of ethanol 
per Kg of body weight in women (equivalent to 43 drinks per month) [19,46]. However, there is a 
clear personal susceptibility of this effect that creates a wide variability range and supposes 
significant inter-individual differences [50,66]. In fact, ACM is considered to be the result of dosage 
and individual predisposition [32].  
Concerning the different effects of beverage choice, ACM may develop through the 
consumption of any type of beverage, such as wine, beer, or spirits, in a lineal dose-dependence 
relationship with the total lifetime dose of ethanol consumed by an individual [38]. In general, 
alcoholic patients consuming >90 g of alcohol a day (approximately seven to eight standard drinks 
per day, considering a standard drink 12–15 g of alcohol) for >5 years are at risk for the development 
of asymptomatic ACM [18]. Wine is considered less damaging compared to other alcohol beverages, 
probably because of its antioxidant polyphenolic content, with molecules such as resveratrol [79,80]. 
The consumption of spirits that contain greater ethanol content may easily induce binge drinking 
and higher cumulated lifetime dose of ethanol, increasing the risk of ACM [19]. 
2.5. The effects of Moderate Consumption of Ethanol and Binge-drinking  
Moderate drinking, considered as the consumption of 20–60 g/day in men (1.5–4 standard 
drinks) and 10–40 g/day in women (1–3 standard drinks), usually is not associated with significant 
cardiotoxicity [19,44]. It does not suppose a risk of ACM development unless consumed over a large 
period of time (more than 10 years) [19,52]. Moderate alcohol consumption has been associated with 
lower risk of heart failure in prior studies of healthy individuals [52] and appears equivalent to 
abstention in improving LV ejection fraction among heavy drinkers with established ACM [81,82].  
Binge drinking, defined as the consumption in men of five or more drinks and four or more 
drinks in women in about two hours, is clearly detrimental for the heart [83,84]. It brings a person’s 
blood ethanol concentration (BAC) to 0.08 grams or higher [85]. It causes acute myocardial effects 
with a temporary depression of LV EF evident in experimental [85,86] and clinical models [87,88]. Is 
more frequent in subjects with LV EF < 40% than in those with preserved LV EF [56]. Acute ethanol 
binge drinking also induces a variety of arrhythmias, known as “Holiday heart Syndrome” [43]. All 
these acute effects produce impairments on the natural course of chronic ACM [62]. Spirits and other 
beverages containing a high percentage of alcohol are more detrimental than wine consumption 
regarding the induction of acute cardiac effects [31,80]. 
2.6. The Effect of Low-dose Ethanol on ACM 
Low-dose ethanol consumption, considered as the daily consumption of up to one standard 
drink for women and two standard drinks for men, has a beneficial effect on preventing coronary 
heart disease [44], heart failure [87], and global mortality [89] as assessed in multiple clinical and 
epidemiological studies with a clear “J-shape” curve of effect [58,90]. However, it is possible with 
low-dose alcohol consumption to achieve an accumulated lifetime dose of ethanol reaching the 
threshold level required to develop ACM in long-term susceptible consumers [19]. This is especially 
possible in those patients more sensitive to the toxic effects of ethanol on the heart, such as women 
[46] and patients with other systemic diseases related to ethanol (cirrhosis, malnutrition, or 
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neurological damage). In addition, some genetic polymorphisms, such as the “DD” isoform for the 
angiotensin-converting enzyme gene [91] and titin truncated-variants [92], are associated with 
higher genetic vulnerability to ACM. Therefore, there is no safe dose of ethanol consumption to 
completely avoid the development of alcohol CMP, with complete abstinence being recommended 
in susceptible subjects [41,45,51].  
2.7. Gender Differences in ACM 
One of the relevant facts in ACM is the existence of a clear gender difference, women being 
more susceptible to the toxic effects of alcohol than men at the same level of lifetime ethanol 
consumption [93,94]. This fact has been assessed with echocardiographic monitoring in women 
consuming high doses of ethanol both in the subclinical period of disease [46] as well as in the 
clinical period when congestive heart failure appears [95]. At the experimental level, some gender 
differences also are evident in functional proteomic analysis, with sex-dependent differences in 
structural and energy-producing myocardial proteins in a rat model of alcoholic cardiomyopathy 
[96]. The biological reason for this gender difference is based on different ethanol absorption rates, 
distribution pattern, and metabolism in women compared to men [52]. Therefore, efforts to prevent 
ACM development in women should be specifically addressed [97]. During pregnancy, ethanol 
consumption should be clearly discouraged because of the possibility of fetal alcohol syndrome or 
the development of other congenital heart diseases [97]. 
3. Pathological Aspects of ACM 
In the course of ethanol-induced cardiac damage, one of the more relevant findings is that 
ethanol exerts its deleterious effects on cardiac myocytes at multiples sites (membrane, receptors, 
mitochondria, ribosomes, sarcolemma, DNA, or cytoskeleton) [18,19,98] (Table 1).  
This is because the ethanol molecule has a small size and is highly reactive, with many cell 
targets. In addition, ethanol has a widespread diffusion because of the potential for distribution 
though biological membranes, achieving targets not only in the membrane receptors and channels 
but also in endocellular particles and at the same nuclear compartment [29,99,100]. This induces a 
variety of effects, since more than 14 different sites in the myocyte can be affected by ethanol [19,98]. 
Thus, ethanol enhances permeation in model membranes by interfering with plasma membrane 
composition and permeability [99], disturbing signaling mechanisms, and activating apoptosis [101], 
as well as disturbing L-Type Ca2+ channel activity [85,86], Na+/K+ ATPase channel activity [102], 
Na+/Ca2+ exchanger activity, and Na+ and K+ channel currents [19,29]. Specifically, ethanol disturbs 
the ryanodine Ca2+ release, the sarcomere Ca2+sensitivity [102,103], the excitation–contraction 
coupling and myofibrillary structure, and protein expression, decreasing heart contraction [86]. 
Ethanol-induced disruption of ribosomal protein synthesis also contributes to non-contractile 
protein depletion [104]. Several aspects of mitochondrial function, including respiratory complex 
activities and mitochondrial-dependent oxidative damage and apoptosis, are also induced by 
ethanol [26,100]. Myocyte cytoskeletal structure [21], connexin channel communication, and 
desmosomal contacts are affected by ethanol, causing structural cell instability [105]. Ethanol may 
induce changes in nuclear regulation of transcription with a dose-dependent translocation of NFkB 
into the nucleus [106]. The resulting effect in those multiple sites may be additive and synergistic, 
increasing the final damage [20,52] (Figure 1). 
3.1. Oxidative and Energy Disturbances in ACM 
Since myocardium requires a high energy supply to maintain persistent sarcomere 
contractions, it was supposed that alcohol could exert its damaging effect on the mitochondrial 
energy supply system, with the disruption of oxidative control mechanisms [26,100]. In fact, 
mitochondrial structural changes have been described in chronic alcohol consumers, with swollen 
megamitochondria and the distortion of inner cristae [107,108]. Functionally high ethanol produces 
disruptions in the myocyte oxidative pattern and decreases in Complex I, II, and IV of the 
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mitochondrial respiratory chain [100,109,110]. As a reflection of this metabolic derangement, 
cytoplasmic lipid droplets and glycogen deposits appear. 
At ultrastructural level, dysfunction on the transition pore in the inner membrane is related to 
ethanol exposure [111]. In addition, ethanol induces mitochondrial-dependent apoptosis pathways 
with Bax and caspase activation [101].  
 
Figure 1. Different effects of ethanol on cardiomyocyte organelles. (Adapted form Nature 451; 
929–936, 2008). Cardiac myocytes are excitable cells with complex signaling and contractile 
structures and are highly sensitive to the toxic effect of alcohol on: (1) plasma membrane composition 
and permeability, signaling, and activation of apoptosis; (2) L-Type Ca2+ channel activity; (3) Na+/K+ 
ATPase channel activity; (4) Na+/Ca2+ exchanger activity; (5) Na+ channel currents; (6) K+ channel 
currents; (7) ryanodine Ca2+ release; (8) sarcomere Ca2+ sensitivity, excitation–contraction coupling, 
myofibrillary structure, and protein expression; (9) several aspects of mitochondrial function, 
including respiratory complex activities; (10) cytoskeletal structure; (11) nuclear regulation of 
transcription; (12) ribosomal protein synthesis; (13) desmosomal contacts; (14) connexin channel 
communication; (15) sarcoglycan complex interactions. 
Table 1. Mechanisms of alcohol-induced heart damage and their effectors. 
Mechanisms Effectors 
Interference with cell signaling and 
calcium transients  MAPK, TGF-β, PKC, PPARγ, MMPs, NF-κβ, PAI-1 
Decrease in excitation–contraction 
coupling mechanisms intracellular [Ca]
2+ transients, L-type Ca2+ channel 
Induction of oxidative damage  ROS, SOD, acetaldehyde 
Pro-inflammatory effect  IL-2, TNF-α, NF-κβ 
Induction of apoptosis  FAS, TNF-α, TGF-β, Bax-Bcl-2, caspases 3,6 
Induction of fibrosis  TLR-4, TGF-β 
Protein-adduct formation  
protein–ethanol adducts 
malondialdehyde–DNA adducts 
Disruption in protein synthesis  
decrease in ribosomal protein synthesis, actin, myosin, 
troponin, titin 
Increased glycogen deposition  glycogen synthase kinase-3β, PARP 
Renin–angiotensin–aldosterone activation  renin, angiotensin, aldosterone, p38 MAPK/Smad 
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Interference in hormone-growth factors  myostatin, ghrelin, leptin, IGF-1 
Interference in regulatory cardiomyokines  FGF21 
Decrease in myocyte regeneration  myostatin, IGF-1 
Impairment of extracellular matrix 
turnover  
cytoskeletal structure, connexin channel, desmosome 
contacts 
Imbalance between cardiac lesions/repair 
mechanisms  
cell apoptosis and necrosis increased myocardial 
fibrosis and decreased myocyte regeneration 
Adapted from Fernández-Solà J and Planavila A, Int J Med Sci 2016, 17, 10. [112]. 
3.2. Ethanol-induced Myocyte Apoptosis and Autophagy 
Myocyte apoptosis, based on assessment of TUNEL staining and caspase activity, has been 
demonstrated to be an active phenomenon leading to myocyte loss in diverse cardiomyopathies 
[113,114] and also in chronic high-dose ethanol consumption both in experimental [109] and clinical 
models [101]. Apoptosis may be induced by ethanol through mitochondrial membrane 
permeabilization and the release of pro-apoptotic factors (cytochrome c) from the mitochondrial 
inter-membrane space to the cytosol. Chronic ethanol exposure, in combination with other stress 
signals, provides a trigger for cardiac apoptosis through activation of the mitochondrial 
permeability transition pore by physiological calcium oscillations [111].  
However, cardiac apoptosis may also develop independently of the mitochondrial pathway 
[115] through the extrinsic pathway, which involves cell surface death receptors [116]. In addition to 
inducing apoptosis, ethanol inhibits the effect of anti-apoptotic molecules such as BCL-2 [101]. 
Ethanol-induced myocyte apoptosis may be regulated by growth factors [117,118] and 
cardiomyokines [119]. The percentage of apoptotic myocytes in ACM is relatively low but, in 
combination with a persistent decrease in myocyte proliferation, they may contribute to an absolute 
cell loss and decreased cardiac contractility [52,115]. Recent data favored a role for micro RNA, such 
as the involvement of miR-378a-5p in cardiomyocyte apoptosis and ACM development through 
ALDH2 gene suppression [120]. 
Recently, apoptosis and necrosis have been also attributed to autophagy in ACM [18]. In order 
to maintain cardiac homeostasis, the removal of defective organelles and cell debris by autophagy is 
essential both in physiological and pathological conditions [115]. Dysregulated excessive autophagy, 
together with other factors such as oxidative stress, neurohormonal activation, and altered fatty acid 
metabolism, contributes to cardiac structural and functional damage following alcoholism. This 
influences the maintenance of cardiac geometry and contractile function, increasing the 
development of ACM [121]. In ACM, protein degradation with sarcomere disarray and contractile 
protein loss has been suggested to be a key point of autophagy induction [18]. Different pathogenic 
hypotheses have been suggested, such as the pivotal role of acetaldehyde [122], the role of oxidative 
stress and stress signaling cascades [109], and the translocation of NFkB into the nucleus [106]. 
Although the mechanism of action behind autophagy and its signaling regulatory cascades remains 
elusive in ACM [121], its understanding may contribute to better identifying molecular mechanisms 
underlying the early stages of alcoholic cardiomyopathy and suggest novel strategies to counteract 
the integrated risk of cardiotoxicity in chronic alcohol consumption [106]. 
3.3. Ethanol-induced Heart Fibrosis  
After myocyte apoptosis or necrosis, the heart tries to repair and regenerate this tissue damage 
[39,123], but the heart regenerative capacity is low as a result of the ethanol aggressive damage and 
develops ineffective repair mechanisms such as progressive fibrosis [124,125]. In fact, ethanol itself 
decreases the myocyte regeneration capacity and increases the fibrogenic process [52,126]. 
Subendocardial and interstitial fibrosis progressively appear in the course of ACM, usually in 
advanced stages [52,56]. More than 30% of the myocyte ventricular fraction can be replaced by 
fibrotic tissue, thus decreasing the heart elasticity and contractile capacity [64] (Figure 2). Some 
cardiomyokines, such as FGF21, may regulate this process of alcohol-induced cardiac fibrosis [119]. 
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Figure 2. Histological lesions in the subclinical and clinical periods of human alcoholic 
cardiomyopathy. Left ventricle apical biopsy. Semithin section. Toluidine blue staining x 400 
magnification. Left: Subclinical period with slight signs of myocytolysis, disarray, and myocyte 
hypertrophy (arrows). Right: End-stage clinical period with myocyte loss, diffuse interstitial fibrosis 
and intense nuclear and myocyte hypertrophy (white arrows). 
3.4. Ethanol Disruption of [Ca2+] Transients and SR Activation 
Since cardiac myocytes are excitable cells, and ethanol may easily damage this 
excitation–contraction mechanism, disruption of this coupling mechanism is involved in the ACM 
pathogenic process [19,58]. Ethanol may produce the modification of sarcolemmal membrane L-type 
Ca2+ channels, leading to a decrease in transmembrane electrically induced Ca2+ transients 
[85,103,127]. One of the most relevant targets of ethanol in the membrane is the disruption of 
membrane receptor composition and activities [86]. The ryanodine L-type Ca2+ receptor at the 
sarcoplasmic reticulum (SR) is also significantly affected by ethanol in a dose-dependent manner 
[86,102]. This causes a decrease in sarcolemmal contraction and also disturbance in other 
intercellular organelles dependent of i.c. [Ca2+] transients [102]. As an adaptive process, chronic 
alcohol consumption induces up-regulation of myocardial L-type [Ca 2+] channel receptors, whose 
activity decreases in the presence of cardiomyopathy [103].  
3.5. Sarcomere Damage and Dysfunction in ACM  
Chronic ethanol misuse clearly depresses protein synthesis and degradation, involving both 
structural and non-structural heart proteins [104,128]. At a pathological level, sarcomere Z-line 
distortion and disruption of the sarcomere pattern leads to myocytolysis [107,129]. Myocytolysis is 
evident through focal myofiber dissolution, cell vacuolization, and fiber disarray [19] (Figure 2). The 
sarcomere complex is early affected by ethanol, decreasing the titin content, a protein that is 
responsible for sarcomere relaxation and LV distensibility [130]. Ethanol also decreases myofilament 
Ca2+ sensitivity [20]. This damage first induces diastolic dysfunction, which is initially subclinical 
and later clinically apparent [57]. In addition, contractile sarcomere proteins such as Myosin, Actin, 
and Troponin are also affected by ethanol, causing the functional progressive depression of myocyte 
contractility, inducing progression to heart failure [56,104,131]. 
3.6. Cardiac Hypertrophy and Remodeling in ACM 
Cardiac remodeling is a global process that myocardium establishes as a result of different 
aggressions [31,132]. Heart myocytes are relatively resistant to the toxic effect of ethanol, developing 
a functional and structural compensatory mechanism able to minimize or repair the ethanol-induced 
myocyte damage [20,31,39]. Structurally, hypertrophy of myocytes is seen in the early stages to 
avoid contractile depression [52,107,125]. Myocytolysis progressively develops, disturbing the 
sarcomere contractile system. The ventricles show wall hypertrophy and compensatory dilatation. 
The heart output is progressively lower in a dose-dependent relationship with the lifetime 
accumulated total dose of alcohol consumed [38]. Several growth factors and cardiomyokines exert 
an autocrine or paracrine effect that tries to compensate for this heart damage [119,133]. Antioxidant, 
anti-inflammatory, anti-apoptotic, and antifibrogenic mechanisms try to avoid myocyte necrosis and 
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heart fibrosis [14,30,58]. The final result is that achieved from the equilibrium between the degree of 
damage and the capacity of heart repair mechanisms in each specific individual [31,56].  
3.7. End-stage ACM 
The heart repair mechanisms that minimize the ethanol-induced cardiac damage are limited 
and apparently ineffective in chronic longstanding scenarios [56,124]. This is usually after more than 
20 years of high ethanol consumption at cumulated lifetime doses higher than 20 Kg ethanol/Kg 
body weight, equivalent to 180 drinks per month [52,134]. The histological pattern of this situation is 
a diffuse myocyte necrosis that is being substituted by interstitial fibrosis and compensatory fiber 
and nuclei hypertrophy of the remaining myocytes [64]. In this scenario, the subject with LV ejection 
fraction < 15% develops frequent episodes of congestive heart failure and ventricular arrhythmias 
[43,61,131]. Systemic involvement of ethanol is usually present, with coexistent liver cirrhosis and 
neurological damage, a fact that worsens the patient prognosis. The mortality of this situation is 
higher than 30% per year, mainly affecting those subjects who persist in ethanol consumption 
[52,54,134].   
4. Prognosis of ACM 
The natural course of ACM is mainly related to the degree of persistence in alcohol 
consumption and the individual biological adaptive response [2,20,41,56,81]. Ethanol abstinence 
allows for recovery in the majority of cases, including in those with previous severe depression of 
LV EF [81,88,135]. On the contrary, subjects who continue drinking at moderate to high doses (more 
than 60 g ethanol/day in men—equivalent to four standard drinks—and 40 g of ethanol/day in 
women—equivalent to 2.5 standard drinks—experience progressive functional and structural 
cardiac impairment, with repeated episodes of cardiac left or congestive failure, arrhythmias, and 
progression to death, with a mortality rate of 10%/year [55,61]. Episodes of binge-drinking are highly 
damaging and should be especially avoided [83]. In these subjects, mortality is related to episodes of 
sudden death and refractory congestive heart failure [42,131,136]. In addition to the risk of other 
ethanol-mediated systemic diseases, liver cirrhosis is the main risk that is highly prevalent in ACM 
[63]. In a follow-up study on ACM, the independent predictors of all-cause mortality were the QRS 
duration, systolic blood pressure, and New York Heart Association classification [137]. In another 
long-term outcome of alcoholic and idiopathic dilated cardiomyopathy, multivariate analysis in the 
entire cohort demonstrated that increased pulmonary capillary wedge pressure, alcoholism, and 
lack of abstinence during follow-up and decreased standard deviation of all normal-to-normal R–R 
intervals were independent predictors of cardiac death [54]. 
Therefore, complete abstinence from ethanol is the most useful measure to control the natural 
course of ACM [51,56,135]. In fact, patients with ACM who abstain from alcohol have a better 
long-term prognosis than subjects with idiopathic dilated CMP [54]. Out of end-stage cases, the 
majority of subjects affected by ACM who achieve complete ethanol abstinence functionally 
improve [33,82,135]. However, subjects with ACM are mostly alcohol-dependent [66,138]. The 
percentage of effective abstinence achievement on these patients submitted to specific programs 
ranges from 50% to 60% [8,9]. Therefore, many ACM subjects are not able to effectively control their 
alcohol-consumption rates. In this group of subjects, it has been demonstrated that the strategy of 
controlled drinking, that supposes to decrease the degree of ethanol consumption to less than 60 
g/ethanol/day is still effective, achieving significantly functional cardiac improvement, although to a 
lesser extent when compared to that obtained in total abstainers [82]. Therefore, any decrease in the 
previous quantity of alcohol consumption may improve, to some degree, cardiac health [51]. Since 
ACM is related to frequent perioperative events and high postoperative morbidity [139], detection 
and treatment of ACM is compulsory to avoid anesthetic and surgical complications [140].  
5. Treatment of ACM 
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The treatment of episodes of heart failure in ACM does not differ from that performed in 
idiopathic-dilated CMP [52,54]. A decrease in cardiac preload with diuretics and postload with 
angiotensin-converting-enzyme inhibitors or beta blockage agents allows for an improvement in 
signs of acute heart failure [19,131]. A reduction of dietary sodium intake is also necessary. 
Nutritional factors are relevant in ACM [67]. A Mediterranean diet, based on monounsaturated fats 
from olive oil, fruits, vegetables, whole grains, and legumes/nuts, has been demonstrated to be 
beneficial for primary prevention of global cardiovascular events (myocardial infarction, stroke, or 
death from cardiovascular causes) [80,141,142]. However, since it includes moderate alcohol 
consumption of red wine, this aspect should be clearly avoided in subjects affected by ACM. The 
exact mechanism by which an increased adherence to the traditional Mediterranean diet exerts its 
favorable effects is not known. However, its beneficial cardiovascular effect may be caused by 
different factors including lipid-lowering, protection against oxidative stress, inflammation and 
platelet aggregation, modification of hormones and growth factors, inhibition of nutrient-sensing 
pathways by specific amino acid restriction, and gut-microbiota-mediated production of metabolites 
influencing metabolic health [143].  
In ACM, it is relevant to consider the treatment of the other alcohol-induced systemic damage, 
such as liver cirrhosis, malnutrition, and vitamin and electrolyte disturbances [2,11,52]. Notably, in 
patients with a history of chronic alcohol consumption complicated by significant myocardial 
dysfunction and chronic malnutrition, re-feeding syndrome may increase the cardiac dysfunction. 
Therefore, physicians should be aware of the risk of new cardiomyopathy in patients with these 
overlapping diagnoses [144]. Control of these alcohol-related systemic diseases, as well as the strict 
control of the presence of other heart risk factors (tobacco, cocaine, arterial hypertension, diabetes 
mellitus, or anemia) contributes to ACM improvement [10,20,23,37,52]. Atrial fibrillation should be 
controlled with chronotropic drugs such as digoxin or diltiazem and anticoagulant treatment to 
avoid arterial embolisms [60,145]. 
In end-stage disease (LV EF < 15%), cardiac transplantation may be the only possibility [146]. In 
those subjects, systemic alcohol-related damage (cancer, liver cirrhosis, or dementia) should also be 
excluded. However, most programs of alcohol transplantation require the guarantee of a long period 
of ethanol abstinence (almost 3 months), a condition not accomplished by most subjects with ACM, 
who are alcohol-dependent [9,66]. Therefore, few patients with end-stage ACM receive heart 
transplantation. In a series of 94 chronic alcoholics with ACM, only 15% achieved heart 
transplantation [56]. 
New strategies to improve the natural course of ACM have been proposed as promising agents 
in this field [112,147]. Since ethanol has multiple cell targets with different pathological mechanisms 
implicated, those different strategies to directly target alcohol-induced heart damage are only 
partially effective and can only be used as support medication in a multidisciplinary approach [112]. 
They try to control myocardial remodeling to avoid the progression of myocyte hypertrophy 
[39,148] or fibrosis [149] and ventricle dysfunction and dilatation, as well as to increase the degree of 
myocyte regeneration [150]. Recently, new cardiomyokines (FGF21, Metrnl) and several growth 
factors (myostatin, IGF-1, leptin, ghrelin, miRNA, and ROCKs inhibitors) have been described as 
being able to regulate cardiac plasticity and decrease cardiac damage, improving cardiac repair 
mechanisms [112,119]. They aim to control oxidative damage, myocyte hypertrophy, interstitial 
fibrosis, and persistent apoptosis. Pharmacological restoration of autophagic reflux by inhibition of 
soluble epoxide hydrolase has been described to ameliorate chronic ethanol-induced cardiac fibrosis 
in an in vivo swine model [151]. In addition to these, stem-cell therapy tries to improve myocyte 
regeneration [112,152]. However, these new strategies have not yet demonstrated their real 
effectiveness in clinical trials, require further evaluation, and are not approved for clinical use [147].  
6. Discussion and Conclusions  
Since ethanol consumption of the global population is not currently under control [2], the 
incidence of alcoholic cardiomyopathy is expected to be maintained in the future, especially in 
specific population groups, such as adolescents and young people [3]. Therefore, efforts for the 
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prevention, early detection, and specific treatment in this relevant disease should be established [45]. 
The direct dose-dependent effect between alcohol intake and development of ACM is clearly 
established [50,52], women being more sensitive than men to the toxic effects of ethanol on the heart 
[46]. However, genetic polymorphisms, the use of other concomitant drugs (tobacco, cocaine), and 
the presence of other cardiac risk factors (hypertension, diabetes) may influence and worsen the 
natural course of ACM in each specific individual [27,72,98]. The multiple sites of myocyte damage 
from alcohol [11,19,23] and the genetically mediated individual predisposition [32,153] create a large 
individual clinical variability and make it difficult to establish a simple effective treatment for ACM 
[27,30,52]. Heart remodeling is an adaptive mechanism, susceptible to being modified in ACM by 
the use of cardiomyokines (FGF21, Metrnl) and growth factors (IGF-1, Myostatin) [112,119]. 
Since ethanol is a drug with systemic toxic effects, the evaluation of global alcohol-related 
systemic damage is necessary in ACM [2]. Control of other cardiac risk factors also allows for a 
better prognosis in ACM [72]. Total abstention from alcohol is the preferred goal [41,51], although 
controlled drinking (with daily consumption < 60 g/day) still allows improvement [82,135]. Binge 
drinking should be absolutely discouraged in ACM [83]. Subjects with ACM who continue in 
high-dose ethanol consumption have a bad prognosis, with repeated episodes of heart failure and 
ventricular arrhythmias leading to a 10% increase in annual mortality rate [56,61]. New strategies 
aiming to control apoptosis, autophagy and pathological heart remodeling, and increase myocyte 
regeneration may be promising in the near future [112,133]. However, areas of uncertainty in this 
complex disease are still present and should be further explored [30]. 
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